RxDoctor Payments DataLook up a doctor →

Maria Hordinsky, MD

Dermatology · Minneapolis, MNNPI 1134152218

Payments from drug & device makers

$2,062,389in general payments, 2019–2025

Across 264 payments — averaging $7812.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$536K
  • Sun Pharmaceutical Industries Inc.$520K
  • Eli Lilly$472K
  • Arcutis Biotherapeutics, Inc.$230K
  • Aclaris Therapeutics, Inc.$123K
  • AbbVie$115K
  • plus $66K from 4 others
$11,683in research payments, 2019–2025

Across 21 payments — averaging $556.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$9K
  • Eli Lilly$2K
  • AbbVie$1K

What the payments were for

  • Consulting fees$67,05079%
  • Travel & lodging$17,08720%
  • Food & beverage$8321%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,062,389 in reported general payments places this provider in the 95th percentile of 273 dermatology providers in Minnesota.

See all dermatology providers in Minnesota

Medicare billing

Part B allowed, 2024
$43,287
Medicare patients
160
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OlumiantBaricitinib23$220,207
Dupixent SyringeDupilumab13$50,593
Dupixent PenDupilumab12$44,601
OpzeluraRuxolitinib Phosphate17$33,892
Clobetasol Propionate175$15,292
Fluocinolone AcetonideFluocinolone/Shower Cap85$4,050
Ketoconazole272$3,840
Tacrolimus24$3,363
Desonide16$2,856
Minoxidil269$2,619
Hydroxychloroquine Sulfate66$2,357
Calcipotriene16$2,102
Ciclopirox25$1,719
Dutasteride59$1,622
Tretinoin13$952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlumiant$32,814$220,20723 claims
Incyte CorporationOpzelura$30,742$33,89217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 273 dermatology providers in Minnesota.

Other dermatology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →